NVOS vs. CNTG, MBRX, GENE, MIRA, AVTX, BCDA, PHXM, GHSI, ELAB, and AIKI
Should you be buying Novo Integrated Sciences stock or one of its competitors? The main competitors of Novo Integrated Sciences include Centogene (CNTG), Moleculin Biotech (MBRX), Genetic Technologies (GENE), MIRA Pharmaceuticals (MIRA), Avalo Therapeutics (AVTX), BioCardia (BCDA), PHAXIAM Therapeutics (PHXM), Guardion Health Sciences (GHSI), Elevai Labs (ELAB), and AIkido Pharma (AIKI). These companies are all part of the "medical" sector.
Novo Integrated Sciences (NASDAQ:NVOS) and Centogene (NASDAQ:CNTG) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, dividends, institutional ownership, profitability, risk, community ranking, earnings, analyst recommendations and valuation.
Centogene received 40 more outperform votes than Novo Integrated Sciences when rated by MarketBeat users.
In the previous week, Centogene had 3 more articles in the media than Novo Integrated Sciences. MarketBeat recorded 3 mentions for Centogene and 0 mentions for Novo Integrated Sciences. Centogene's average media sentiment score of 0.22 beat Novo Integrated Sciences' score of 0.00 indicating that Centogene is being referred to more favorably in the news media.
Centogene has a net margin of 0.00% compared to Novo Integrated Sciences' net margin of -88.48%. Centogene's return on equity of 0.00% beat Novo Integrated Sciences' return on equity.
Novo Integrated Sciences has higher earnings, but lower revenue than Centogene.
5.7% of Novo Integrated Sciences shares are owned by institutional investors. Comparatively, 9.9% of Centogene shares are owned by institutional investors. 10.9% of Novo Integrated Sciences shares are owned by insiders. Comparatively, 1.9% of Centogene shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Novo Integrated Sciences has a beta of -1.91, indicating that its stock price is 291% less volatile than the S&P 500. Comparatively, Centogene has a beta of -0.67, indicating that its stock price is 167% less volatile than the S&P 500.
Summary
Centogene beats Novo Integrated Sciences on 9 of the 11 factors compared between the two stocks.
Get Novo Integrated Sciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for NVOS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding NVOS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Novo Integrated Sciences Competitors List
Related Companies and Tools
